BRAF and melanoma: However, magnetic resonance imaging shows uptake of gadolinium contrast dye in melanoma brain metastases and the BRAF inhibitors vemurafenib and dabrafenib show clinical activity, albeit limited, in melanoma patients with brain metastases [10,11], suggesting leakage of the blood–brain barrier in melanoma brain metastases.